India's Ranbaxy Expects U.S. FDA Clearance For Two Production Plants
This article was originally published in PharmAsia News
Executive Summary
Ranbaxy Laboratories of India is expected to emerge from its persona-non-grata status with the U.S. FDA soon, settling a three-year-old dispute over production quality at some of its plants